ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life Prolonging Therapy in mHSPC скачать в хорошем качестве

ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life Prolonging Therapy in mHSPC

Andrew J. Armstrong, MD, ScM, FACP, Professor and Director of Research at Duke Cancer Institute Center for Prostate and Urologic Cancers and lead author of the ARCHES study, gives an overview of the ARCHES trial and related ENZAMET trial, which demonstrated showed the use of enzalutamide improved survival and reduced disease progression in men with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Armstrong compares enzalutamide to first-generation androgen receptor inhibitors such as flutamide and bicalutamide, discusses the strong results supporting enzalutamide in both trials, and the implications for future mHSPC treatment using androgen deprivation.